Next Article in Journal
siRNA Genome Screening Approaches to Therapeutic Drug Repositioning
Previous Article in Journal
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
Previous Article in Special Issue
Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer’s Disease
Pharmaceuticals 2013, 6(1), 108-123; doi:10.3390/ph6010108
Review

Neurotransmitter CART as a New Therapeutic Candidate for Parkinson’s Disease

1,2,3,* , 4,5, 2 and 1,3,*
Received: 5 November 2012 / Revised: 13 December 2012 / Accepted: 14 January 2013 / Published: 18 January 2013
(This article belongs to the Special Issue Mitochondrial Drugs for Neurodegenerative Diseases)
View Full-Text   |   Download PDF [241 KB, 21 January 2013; original version 18 January 2013]   |   Browse Figures

Abstract

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases. To date, there is no effective treatment that halts its progression. Increasing evidence indicates that mitochondria play an important role in the development of PD. Hence mitochondria-targeted approaches or agents may have therapeutic promise for treatment of the disease. Neuropeptide CART (cocaine-amphetamine-regulated transcript), a hypothalamus and midbrain enriched neurotransmitter with an antioxidant property, can be found in mitochondria, which is the main source of reactive oxygen species. Systemic administration of CART has been found to ameliorate dopaminergic neuronal loss and improve motor functions in a mouse model of PD. In this article, we summarize recent progress in studies investigating the relationship between CART, dopamine, and the pathophysiology of PD, with a focus on mitochondria-related topics.
Keywords: cocaine- and amphetamine- regulated transcript; mitochondria; antioxidant; dopamine; oxidative stress; neuroprotection cocaine- and amphetamine- regulated transcript; mitochondria; antioxidant; dopamine; oxidative stress; neuroprotection
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Mao, P.; Meshul, C.K.; Thuillier, P.; Reddy, P.H. Neurotransmitter CART as a New Therapeutic Candidate for Parkinson’s Disease. Pharmaceuticals 2013, 6, 108-123.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert